Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice

In this study, an isoproterenol (ISO)-induced pathological cardiac hypertrophy model was established to investigate the protective effect of omaveloxolone in vivo and in vitro. Our study first confirmed that omaveloxolone administration improved ISO-induced pathological cardiac hypertrophy in mice and neonatal cardiomyocytes. Omaveloxolone administration also diminished ISO-induced cardiac oxidative stress, inflammation and cardiomyocyte apoptosis. In addition, omaveloxolone administration activated the Nrf2 signaling pathway, and Nrf2 knockdown almost completely abolished the cardioprotective effect of omaveloxolone, indicated that the cardioprotective effect of omaveloxolone was directly related to the activation of the Nrf2 signaling. In summary, our study identified that omaveloxolone may be a promising therapeutic agent to mitigate pathological cardiac hypertrophy in the future.PMID:38145457 | DOI:10.1080/10715762.2023.2299359

Source: Free Radical Research - December 25, 2023 Category: Research Authors: Li Xianchao Yang Wu Yunzhao Yang Yaohua Wu Xi Yu Wenjuan Hu Source Type: research